Growing Optimism for Newly Diagnosed Myeloma/High-Risk Disease: MCRT Interactive Webcast on November 21

Growing Optimism for Newly Diagnosed Myeloma/High-Risk Disease: MCRT Interactive Webcast on November 21

November 21 @ 11:00 — 4:15pm New York

Choose to attend one or both of two 2 1/2 hour sessions, one registration covers both sessions.The faculty for the first session of the Myeloma Crowd Round Table Interactive Webcast will explain “Why We’re Optimistic About Newly Diagnosed Myeloma.” Fear, uncertainty, and pessimism accompany virtually every cancer diagnosis, especially if most patients, like those with myeloma, have never even heard the word before. Yet myeloma specialists are increasingly confident and optimistic that the vast majority of diagnosed patients have legitimate paths toward longevity, good quality of life, and will benefit from increasing treatment options and experience. High-risk disease, the focus of the second session, poses the most difficult questions in myeloma treatment. Increasing knowledge about genetic differentiation provides information about which features to target and treat. And although most new medications are generally approved for patients who have had many lines of treatment, they are increasingly being used as front-line treatments for high-risk disease patients with encouraging results. These and other topics will be discussed by the faculty.

Schedule & Agenda

November 21 @ 11:00 — 4:15pm New York

11:00am

Jennifer Ahlstrom, Founder and President

Session One: Why We’re Optimistic About Newly Diagnosed Myeloma

Welcome and Introduction

11:05am

Leif Bergsagel, MD, Mayo Clinic

Session One: Why We’re Optimistic About Newly Diagnosed Myeloma

An overview of the history of progress in myeloma research and treatment.

11:25am

Matthew Fero, MD, FACP, University of New Mexico Comprehensive Cancer Center

Session One: Why We’re Optimistic About Newly Diagnosed Myeloma

Therapeutic options available to newly diagnosed patients.

11:45am

Edward Libby, MD, Seattle Cancer Care Alliance

Session One: Why We’re Optimistic About Newly Diagnosed Myeloma

How patients should balance their expectations today with those in the foreseeable future.

12:05pm

Sarah Lee, MD, Seattle Cancer Care Alliance

Session One: Why We’re Optimistic About Newly Diagnosed Myeloma

A moderated discussion with two case studies.

12:25pm

Full Faculty

Session One: Why We’re Optimistic About Newly Diagnosed Myeloma

Audience Questions & Answers

1:30pm

Rozalynn Hite, Program Director

Myeloma Coach Program

An overview of the Myeloma Coach Program

1:40pm

Jennifer Ahlstrom, Founder and President

Session Two: High-Risk Disease

Welcome and Introduction of Faculty

1:45pm

Sarah Holstein, MD, PhD, University of Nebraska Medical Center

Session Two: High-Risk Disease

An overview of the current state of knowledge about high-risk disease.

2:05pm

Parameswaran Hari, MD, MS, Medical College of Wisconsin

Session Two: High-Risk Disease

The range of treatment options available for high-risk disease.

2:25pm

Andrew Cowan, MD, Seattle Cancer Care Alliance

Session Two: High-Risk Disease

Emerging therapeutic options that give physicians greater optimism about treating high-risk disease.

2:45pm

David Coffey, MD, Seattle Cancer Care Alliance

Session Two: High-Risk Disease

A moderated discussion with two case studies.

3:05pm

Full Faculty

Session Two: High-Risk Disease

Audience Questions & Answers

4:10pm

Jennifer Ahlstrom, Founder and President

Session Two: High-Risk Disease

Closing

Speakers & Moderators

Jennifer Ahlstrom

Jenny A - Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials...

Read Bio

Rozalynn Hite

Rozalynn Hite is the Myeloma Coach Director and wife of myeloma patient Richard Hite. Rozalynn is an occupational therapist and mother of three beautiful children....

Read Bio

Greg Brozeit

Greg is the Program Director for the Myeloma Crowd patient education programs. He is based in Northeast Ohio....

Read Bio

Leif Bergsagel, MD

Leif Bergsagel, MD, is among the top researchers in the world who studies the molecular pathogenesis of multiple myeloma. His laboratory is focused on understanding the molecular e...

Read Bio

Sarah Lee, MD

Dr. Lee is a hematologist-oncologist who specializes in the care of patients with plasma cell disorders. Before joining SCCA, she completed a fellowship in hematology-oncology at t...

Read Bio

Sarah Holstein, MD, PhD

Dr. Holstein is a physician-scientist who specializes in the treatment of multiple myeloma and related plasma cell dyscrasias. Prior to joining the faculty at UNMC, Dr. Holstein se...

Read Bio

Paramesewaran Hari, MD, MS

Parameswaran Hari, MD, MS, is the Armand J. Quick/William F. Stapp Professor of Hematology at Medical College of Wisconsin. Dr. Hari serves as Chief of the Division of Hematology a...

Read Bio

Andrew Cowan, MD

Dr Cowan is an assistant professor at UW and Fred Hutch in the division of medical oncology where he focuses on care and research of patients with multiple myeloma and AL amyloidos...

Read Bio

David Coffey

David Coffey, M.D. is a physician scientist at the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance. He specializes in the treatment of multiple myeloma inc...

Read Bio

About the Myeloma Crowd Round Tables (MCRTs)

About the Myeloma Crowd Round Tables (MCRTs)

Myeloma Crowd Round Tables (MCRTs) are education programs for myeloma patients and caregivers on a variety of treatment and research issues.  Each MCRT features presentations from internationally-recognized myeloma experts who also take extensive Q&A sessions from audience members.

Register Today!

November 21 @ 11:00 — 4:15pm New York

Event Sponsors





Thanks to our Myeloma Crowd Community sponsors:

.